Therapy News and Research

RSS

MiRNA-21 interferes with Herceptin therapy, says study

Overexpression of a specific type of microRNA can derail treatment by disabling an important molecular brake on breast cancer cell proliferation, according to evidence presented by researchers from The University of Texas M. D. Anderson Cancer Center at the American Association for Cancer Research 101st Annual Meeting 2010.

17 Apr 2010

Intensive rehabilitation therapy with robotic aids can help stroke patients regain limb movement

Patients show modest yet meaningful gains in limb movement and an improved outlook on life years after suffering a stroke, a major clinical study has found. The paper, published online this week in the New England Journal of Medicine, provides the best evidence yet that stroke sufferers in a controlled study can regain limb movement long after an injury, through intensive therapy with specially trained personnel and newly created robotic aids.

17 Apr 2010

Marker found in iPS cells correlates with levels of pluripotency: Researchers

Researchers in China are reporting that they have found a way to determine which somatic cells -- or differentiated body cells -- that have been reprogrammed into a primordial, embryonic-like state are the most viable for therapeutic applications.

17 Apr 2010

Updated clinical guidelines presented at EAU Anniversary Congress

A number of updated guidelines are presented at the Anniversary Congress of the European Association of Urology (EAU) held in Barcelona, from 16 through 20 April. The abridged versions - Pocket Guidelines - which are based on the extended text documents will also be available in Barcelona to all EAU members and press.

17 Apr 2010

New drug to stop the growth of prostate cancer tumors investigated

The American Cancer Society estimates one man in six will get prostate cancer during his lifetime, making it the second-leading cause of cancer death in men. With a new partnership with Areva Med, UC researchers will investigate the use of a new drug in stopping the growth of prostate cancer tumors.

17 Apr 2010

Dance-based therapy can improve balance and gait, and reduce falls in older persons

For seniors, dancing isn't just for fun; it also can be therapeutic. Two recent studies conducted by University of Missouri researchers found that participation in dance-based therapy can improve balance and gait in older adults. Improved functionality among seniors can decrease their risk of falling and reduce costly injuries.

17 Apr 2010

Multinational phase II study: GS-9450 can reduce markers of liver damage in patients with NASH

Results from a multinational phase II study presented today at the International Liver CongressTM 2010 have shown that treatment with the caspase inhibitor GS-9450 can reduce markers of liver damage in patients with non-alcoholic steatohepatitis (NASH - the most serious form of non-alcoholic liver disease) as demonstrated by reduced levels of alanine and aspartate aminotransferases, hepatic enzymes that indicate cell damage.

17 Apr 2010

Men with prostate cancer may face increased risk of thromboembolism

Men with prostate cancer, particularly those receiving hormone therapy, may face an increased risk of blood clots or 'thromboembolism', scientists at King's College London have found.

17 Apr 2010

Treatment with high dose UDCA no more effective for NASH: German study

Results of a German study presented today at the International Liver CongressTM 2010, the Annual Meeting of the European Association for the Study of Liver in Vienna, Austria, have shown that overall, treatment with high dose (23-28mg/kg/d) ursodeoxycholic acid is no more effective than placebo in the treatment of non-alcoholic steatohepatitis, the most advanced form of non-alcoholic liver disease associated with cirrhosis of the liver.

17 Apr 2010

Genentech's Tarceva receives FDA approval as maintenance therapy for advanced NSCLC

Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration approved the daily pill Tarceva® (erlotinib) as a maintenance treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.

17 Apr 2010

U.S. Patent Office issues Notices of Allowance covering PLC Systems's RenalGuard technology

PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today reported that the U.S. Patent and Trademark Office had issued Notices of Allowance for two of PLC's patent applications associated with its RenalGuard® technology.

16 Apr 2010

3M files lawsuit against Andover Healthcare over CoFlex 2 Layer Compression System

3M and 3M Innovative Properties Co. filed a lawsuit in the U.S. District Court for the District of Minnesota today against Andover Healthcare Inc. seeking injunctive relief and damages regarding Andover's CoFlex 2 Layer Compression System.

16 Apr 2010

Serametrix announces commercial launch of serum test for measuring serum antibodies

Serametrix has announced the commercial launch of a serum test for measuring serum antibodies to the important tumor antigen NY-ESO-1. The test will be offered as a service to drug companies and clinicians for correlative studies, monitoring and potentially predicting patient responses to cancer treatments.

16 Apr 2010

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Findings published today in The New England Journal of Medicine from a first-of-its-kind comparator trial evaluating the anti-tumor necrosis factor (TNF)-alpha biologic treatment REMICADE (infliximab) in the treatment of moderately to severely active Crohn's disease in patients who were naive to immunomodulator and biologic therapy, showed that a significantly greater proportion of patients receiving REMICADE achieved steroid-free remission and mucosal healing compared with patients receiving azathioprine.

16 Apr 2010

Diabetic mice generate new insulin-producing cells following extreme cell destruction

Type 1 diabetes is the most common cause of diabetes in children, although it may occur at any age. Also called juvenile diabetes, this pathology usually results from autoimmune destruction of insulin-producing cells of the pancreas.

16 Apr 2010

New therapeutic approach for Duchenne muscular dystrophy

Researchers from Universit- Laval's Faculty of Medicine and the CHUQ Research Center have proven that it is possible to repair the defective gene responsible for Duchenne muscular dystrophy.

16 Apr 2010

Alexion Pharmaceuticals' Soliris NDA for PNH receives approval in Japan

Alexion Pharmaceuticals, Inc. and Alexion Pharma International Sàrl today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the Company's New Drug Application (NDA) for the use of Soliris® (eculizumab) as a treatment for patients in Japan with paroxysmal nocturnal hemoglobinuria (PNH).

16 Apr 2010

New nanotechnology biomedical therapy for joint injuries

Dr. Nirav A. Shah, MD, an orthopaedic sports medicine surgeon affiliated with Palos Community Hospital is the first to design a new nanotechnology biomedical therapy that promotes the growth of new, stronger cartilage to aid in the treatment of joint injuries.

16 Apr 2010

1440 nm wavelength beneficial in laser-assisted lipolysis for fat-disruption and tissue tightening

Cynosure, Inc. today announced the presentation of a new study that demonstrates the clinical benefits of using a 1440 nm wavelength in laser-assisted lipolysis to disrupt fat tissue and tighten skin through tissue coagulation. The study, led by Barry DiBernardo, M.D., Medical Director of New Jersey Plastic Surgery, is one of six Cynosure-related abstracts being presented this week at the 2010 American Society for Laser Medicine and Surgery (ASLMS) Annual Conference in Arizona.

16 Apr 2010

Revlimid now available to multiple myeloma patients in Nova Scotia

Following the broadcast on CTV's W5 of the plight of multiple myeloma patient Frank Boyd and his inability to obtain appropriate drug treatment, on March 27, the President of Myeloma Canada, John Lemieux, immediately wrote to the Honourable Maureen MacDonald, Minister of Health of Nova Scotia urging her to implement an interim arrangement to ensure that Revlimid is available to multiple myeloma patients, including Mr. Boyd, in Nova Scotia.

16 Apr 2010

Therapy News and Research

MiRNA-21 interferes with Herceptin therapy, says study

Intensive rehabilitation therapy with robotic aids can help stroke patients regain limb movement

Marker found in iPS cells correlates with levels of pluripotency: Researchers

Updated clinical guidelines presented at EAU Anniversary Congress

New drug to stop the growth of prostate cancer tumors investigated

Dance-based therapy can improve balance and gait, and reduce falls in older persons

Multinational phase II study: GS-9450 can reduce markers of liver damage in patients with NASH

Men with prostate cancer may face increased risk of thromboembolism

Treatment with high dose UDCA no more effective for NASH: German study

Genentech's Tarceva receives FDA approval as maintenance therapy for advanced NSCLC

U.S. Patent Office issues Notices of Allowance covering PLC Systems's RenalGuard technology

3M files lawsuit against Andover Healthcare over CoFlex 2 Layer Compression System

Serametrix announces commercial launch of serum test for measuring serum antibodies

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Diabetic mice generate new insulin-producing cells following extreme cell destruction

New therapeutic approach for Duchenne muscular dystrophy

Alexion Pharmaceuticals' Soliris NDA for PNH receives approval in Japan

New nanotechnology biomedical therapy for joint injuries

1440 nm wavelength beneficial in laser-assisted lipolysis for fat-disruption and tissue tightening

Revlimid now available to multiple myeloma patients in Nova Scotia

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News